Impact That Matters
Therapeutic Research In Accelerated Discovery (TRIAD)TRIAD = Academia + Government + Industry
TRIAD Partners
Our TRIAD partners include innovative biotech & pharmaceutical companies, award-winning researchers at top-tier universities, and those spanning the drug discovery, drug development, and diagnostics continuum for Charcot-Marie-Tooth research.
Partnerships vary depending on research goals, milestones met in preclinical or clinical development, and strategic alliance agreements.
TRIAD & GRIN
As part of TRIAD, in 2013, the Global Registry for Inherited Neuropathies (GRIN) was developed to conduct patient-focused research & development for treatments and cures. The patient voice is at the forefront of all we do. By incorporating the patient voice from the beginning, our research programs have the greatest potential for success. HNF funds research with one goal in mind; advancing to clinical trials for Charcot-Marie-Tooth research.
TRIAD Council
The TRIAD Council is composed of CMT thought leaders, experts, and consultants engaged in collaborative planning and decision-making to provide regular guidance and direction to our research strategy. This network of professionals reviews grant proposals, provides expert guidance, and assesses project outcomes to advance therapeutic development for CMT.
Our most recent TRIAD partnerships & initiatives
Click on the logos for more information.
Click on the logos for more information.
Click on the logos for more information.
Click on the logos for more information.
HNF participates and supports an advocacy role by providing real-world data to the FDA and other stakeholders. Our critical data facilitates improved knowledge of the lived experience of CMT patients and the advancement of clinical development.
Learn more on this topic
Latest News and Related Blog Posts
Hot off the press
Some recent papers on Charcot-Marie-Tooth (CMT) disease go to show that we are steadily and impressively peeling back the complexity of the biology even though it is a relatively common rare disease with several thousand publications on it.